| Should all papillary thyroid microcarcinomas be aggressively treated?: an analysis of 18,445 cases XM Yu, Y Wan, RS Sippel, H Chen Annals of surgery 254 (4), 653-660, 2011 | 373 | 2011 |
| Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy DY Greenblatt, KJ Kelly, V Rajamanickam, Y Wan, T Hanson, ... Annals of surgical oncology 18, 2126-2135, 2011 | 335 | 2011 |
| Risk stratification for distal pancreatectomy utilizing ACS-NSQIP: preoperative factors predict morbidity and mortality KJ Kelly, DY Greenblatt, Y Wan, RJ Rettammel, E Winslow, CS Cho, ... Journal of Gastrointestinal Surgery 15 (2), 250-261, 2011 | 124 | 2011 |
| Indirect costs associated with metastatic breast cancer Y Wan, X Gao, S Mehta, Z Wang, C Faria, L Schwartzberg Journal of medical economics 16 (10), 1169-1178, 2013 | 71 | 2013 |
| Perioperative safety and volume: outcomes relationships in bariatric surgery: a study of 32,000 patients JC Gould, CK Kent, Y Wan, V Rajamanickam, G Leverson, GM Campos Journal of the American College of Surgeons 213 (6), 771-777, 2011 | 49 | 2011 |
| Quality-adjusted survival with combination nal-IRI+ 5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q … U Pelzer, JF Blanc, D Melisi, A Cubillo, DD Von Hoff, A Wang-Gillam, ... British journal of cancer 116 (10), 1247-1253, 2017 | 39 | 2017 |
| Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized … MS Niederman, J Chastre, CT Solem, Y Wan, X Gao, DE Myers, S Haider, ... Clinical therapeutics 36 (9), 1233-1243. e1, 2014 | 39 | 2014 |
| Quality-adjusted survival with combination nab-paclitaxel+ gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis M Reni, Y Wan, C Solem, S Whiting, X Ji, M Botteman Journal of medical economics 17 (5), 338-346, 2014 | 27 | 2014 |
| Eliciting health state utilities for Dupuytren’s contracture using a discrete choice experiment NY Gu, MF Botteman, RA Gerber, X Ji, R Postema, Y Wan, G Sianos, ... Acta orthopaedica 84 (6), 571-578, 2013 | 27 | 2013 |
| Laparoscopy improves short-term outcomes after surgery for diverticular disease AJ Russ, KL Obma, V Rajamanickam, Y Wan, CP Heise, EF Foley, ... Gastroenterology 138 (7), 2267-2274. e1, 2010 | 26 | 2010 |
| Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel CJ Langer, V Hirsh, I Okamoto, FJ Lin, Y Wan, S Whiting, TJ Ong, ... British journal of cancer 113 (1), 20-29, 2015 | 25 | 2015 |
| Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish … J Rello, M Nieto, J Sole-Violan, Y Wan, X Gao, CT Solem, ... Medicina Intensiva (English Edition) 40 (8), 474-482, 2016 | 17 | 2016 |
| Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus and treated with linezolid or vancomycin: a secondary … Y Wan, Q Li, Y Chen, S Haider, S Liu, X Gao Journal of Medical Economics 19 (1), 53-62, 2016 | 15 | 2016 |
| Quality-adjusted survival with nab-paclitaxel versus standard paclitaxel in metastatic breast cancer: a Q-TWiST analysis J Cortes, J Pérez-García, S Whiting, Y Wan, C Solem, MH Tai, ... Clinical breast cancer 18 (5), e919-e926, 2018 | 11 | 2018 |
| The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis A Shelbaya, CT Solem, C Walker, Y Wan, C Johnson, JC Cappelleri ClinicoEconomics and Outcomes Research, 213-222, 2018 | 10 | 2018 |
| Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data CT Solem, A Shelbaya, Y Wan, CG Deshpande, J Alvir, E Pappadopulos Neuropsychiatric Disease and Treatment, 2755-2764, 2016 | 9 | 2016 |
| Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in … U Pelzer, JF Blanc, D Melisi, A Cubillo, DD Von Hoff, A Wang-Gillam, ... Journal of Clinical Oncology 34 (15_suppl), e15732-e15732, 2016 | 7 | 2016 |
| Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer EG Chiorean, D Von Hoff, Y Wan, S Margunato-Debay, M Botteman, ... Cancer Management and Research, 1389-1396, 2018 | 5 | 2018 |
| IN4 Health care resource utilization (HCRU) and costs among patients treated for nosocomial pneumonia (NP) caused by methicillin resistant Staphylococcus aureus (MRSA … CT Solem, MS Niederman, J Chastre, Y Wan, X Gao, DE Myers, S Haider, ... Value in Health 15 (4), A10, 2012 | 5 | 2012 |
| Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma CH Lee, Y Wan, A Smith, R Xie, RJ Motzer European urology open science 31, 1-9, 2021 | 4 | 2021 |
Xiao-Min YuUniversity of Wisconsin Madison在 surgery.wisc.edu 的电子邮件经过验证
Xiao-Min YuUniversity of Wisconsin Madison在 surgery.wisc.edu 的电子邮件经过验证